Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease

BACKGROUND: The treatment paradigm for metastatic hormone-sensitive prostate cancer (mHSPC) patients is evolving. PET/CT now offers improved sensitivity and accuracy in staging. Recent randomized trial data supports escalated hormone therapy, local primary tumor therapy, and metastasis-directed ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Neil R., Huiza, Claudia, Patel, Jill S., Tsai, Sonny, Kalpage, Nathisha, Thein, May, Pitcher, Sage, Lee, Steve P., Inouye, Warren S., Jordan, Mark L., Sanati, Homayoon, Jafari, Lida, Bennett, Carol J., Gin, Greg E., Kishan, Amar U., Reiter, Robert E., Lewis, Michael, Sadeghi, Ahmad, Aronson, William J., Garraway, Isla P., Rettig, Matthew B., Nickols, Nicholas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444674/
https://www.ncbi.nlm.nih.gov/pubmed/30935383
http://dx.doi.org/10.1186/s12885-019-5496-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444674/
https://www.ncbi.nlm.nih.gov/pubmed/30935383
http://dx.doi.org/10.1186/s12885-019-5496-5

Ejemplares similares